# Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC

> **NCT06123754** · PHASE3 · RECRUITING · sponsor: **3D Medicines (Sichuan) Co., Ltd.** · enrollment: 390 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Envalfolimab subcutaneously injected+Platinum-based doublet chemotherapy intravenous injection
- **DRUG:** placebo subcutaneously injected +Platinum-based doublet chemotherapy intravenous injection

## Key facts

- **NCT ID:** NCT06123754
- **Lead sponsor:** 3D Medicines (Sichuan) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-17
- **Primary completion:** 2027-12-30
- **Final completion:** 2027-12-30
- **Target enrollment:** 390 (ESTIMATED)
- **Last updated:** 2026-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06123754

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06123754, "Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06123754. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*